AMGN Downgraded by HSBC -- Price Target Lowered to $425
HSBC downgraded Amgen (AMGN) to 'Hold' from 'Buy', lowering its price target to $425 from $445. GuruFocus values AMGN at $365.87, suggesting a 6.1% overvaluation. Insider selling and mixed guru activity are noted, with AMGN's GF Score at 86/100.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short-term selling, but fundamentals remain solid.
Market read
Analyst downgrade could pressure AMGN stock; investors should monitor price action and insider activity.
What to watch
Recent Horizon Therapeutics acquisition may provide pipeline upside not fully reflected in the downgrade.
Background
Amgen is a $210B biotech leader with recent insider selling and mixed guru sentiment.
Ticker impact
HSBC downgraded Amgen to Hold and cut the price target to $425, indicating limited upside.
Short-term price decline of 2‑4% pending market reaction.
Downgrade with lower target suggests reduced upside; insider selling reinforces bearish bias.
Market effects
Biotech sector may see modest pressure as a large-cap peer faces a downgrade.
U.S. healthcare stocks could experience slight pullback.
Limited; primarily affects U.S. investors focused on Amgen.
Counterpoint
Despite the downgrade, Amgen's strong profitability and growth scores could support a hold or buy for long-term investors.
Key entities
- AnalystHSBC
Downgraded Amgen to Hold and lowered price target.
- CompanyAmgen Inc.
Biotech firm subject of downgrade.
